Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous anifrolumab added to standard care in adults with polymyositis or dermatomyositis
MOH_2023-11-09_013038Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anifrolumab in Autoimmune Myopathies, polymyositis (PM) and dermatomyositis (DM) (3 arms), sponsored by AstraZeneca. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
anifrolumab
03
Conditions
Autoimmune Myopathiespolymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on MOH_2023-11-09_013038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-09_013038.